Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy.
A 46-year-old woman, with biopsy proven pulmonary sarcoidosis, was referred for an [18F]-FDG PET/CT scan that depicted multivisceral involvement and an unusual [18F]-FDG focus located in the pituitary fossa consistent with pituitary sarcoidosis. This was confirmed by decreased antidiuretic hormone blood levels and contrast-enhanced CT scan. This unsuspected neurosarcoidosis prompted corticosteroid therapy. A [18F]-FDG-PET/CT examination performed 10 weeks after initiation of treatment revealed complete recovery. It is suggested that the skull base should be included in the PET scanning of patients with sarcoidosis. [18F]-FDG imaging may be useful in the early evaluation of response to treatment.
Aide
N
N
Hôpitaux de Paris PET centre, Department of Radiology, Paris, France.
Benayoun
M
M
Kerrou
K
K
Khalil
A
A
Cadranel
J
J
Talbot
J N
JN
D005260:Female; D019788:Fluorodeoxyglucose F18; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010900:Pituitary Diseases / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012507:Sarcoidosis / Q000000981:diagnostic imaging* / Q000188:drug therapy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D005938:Glucocorticoids; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18